ã¡ãã£ã¢èšäº
ã¢ã«ããã€ããŒç
ã®æ°è¬ ç±³FDAæ¿èªãšçºè¡š ãšãŒã¶ã€ãå
±åéçº
ããºãææ°ããŒã¯ 368
twitterã³ã¡ã³ã 345ä»¶äž 301ïœ345ä»¶
ããã¯ããããã¥ãŒã¹ã ïŒ
æ¬åœãªãæãé£ã
ç¥æ¯ãã¢ã«ããã€ããŒã ã£ãããã
ïŒå€å䟿ä¹ããå¥åº·é£åãããããããåºãã ãããã©ïŒ
ã¢ã«ããã€ããŒç ã®æ°è¬ ç±³FDAæ¿èªãšçºè¡š ãšãŒã¶ã€ãå ±åéçº
ç¥æ¯ãã¢ã«ããã€ããŒã ã£ãããã
ïŒå€å䟿ä¹ããå¥åº·é£åãããããããåºãã ãããã©ïŒ
ã¢ã«ããã€ããŒç ã®æ°è¬ ç±³FDAæ¿èªãšçºè¡š ãšãŒã¶ã€ãå ±åéçº
广ã¯èªãããã€ã€ãè¿
éèªèšŒãªã®ã§ä»åŸã®èšåºè©Šéšæ¬¡ç¬¬ã§ã¯åãæ¶ãããããããããªãããã§ã
ãšã¯ããããããã
ãšã¯ããããããã
æå ±ãããïŒ
â
ã¢ã«ããã€ããŒç ã®æ°è¬ ç±³FDAæ¿èªãšçºè¡š
ãšãŒã¶ã€ãå ±åéçº
â
ã¢ã«ããã€ããŒç ã®æ°è¬ ç±³FDAæ¿èªãšçºè¡š
ãšãŒã¶ã€ãå ±åéçº
ã¢ã«ããã€ããŒç
ã®æ°è¬ ç±³FDAæ¿èªãšçºè¡š ãšãŒã¶ã€ãå
±åéçº | å»ç
ããã¯æå ±ã§ãã
ãã®æ°è¬ã§è³å ã®ã¢ããã€ãÎ²ãæžå°ãããªãããããŸã§supportiveãªæ©èœãããªãã£ãã¢ã«ããã€ããŒç æ²»çè¬ãšã¯éã£ãŠãããçšåºŠæ ¹æ¬çãªæ²»çãæåŸ ãããŸãã
ãã®æ°è¬ã§è³å ã®ã¢ããã€ãÎ²ãæžå°ãããªãããããŸã§supportiveãªæ©èœãããªãã£ãã¢ã«ããã€ããŒç æ²»çè¬ãšã¯éã£ãŠãããçšåºŠæ ¹æ¬çãªæ²»çãæåŸ ãããŸãã
FDAã£ãŠæ¥æ¬ã®åçåŽåçã¿ãããªããããããã¢ã«ããã€ããŒã®æ²»çè¬ãšããŠèªå¯ããã£ãŠãã¡ããããã
ã¢ã«ããã€ããŒç ã®æ°è¬ ç±³FDAæ¿èªãšçºè¡š ãšãŒã¶ã€ãå ±åéçº
ã¢ã«ããã€ããŒç ã®æ°è¬ ç±³FDAæ¿èªãšçºè¡š ãšãŒã¶ã€ãå ±åéçº
ç±³ã®ããã€ãªãžã§ã³ããšæ¥æ¬ã®ããšãŒã¶ã€ããå
±åéçºããã¢ã«ããã€ããŒç
ã®æ°è¬ãã¢ãã¥ã«ãããããç±³FDAãæ¿èªãã¢ã«ããã€ããŒç
ã®æ°è¬ãæ¿èªãããã®ã¯2003幎以æ¥18幎ã¶ããã¢ããã€ãβã«äœçšããæ²»çè¬ã¯åããŠ
ãŸãäžæ©
ãä»åã®æ¿èªã¯æ·±å»ãªç
æ°ã®æ£è
ã«æ©æã«æ²»çãæäŸããããã®ãè¿
éæ¿èªããšããä»çµã¿ã§è¡ããããããFDAã¯è¿œå ã®èšåºè©Šéšã§æ€èšŒããå¿
èŠããããšããŠããŠããã®çµæã广ãèªããããªãå Žåã«ã¯æ¿èªãåãæ¶ãããšããããšããŠããŸããã
ãããããã¢ãã¥ã«ãããæ°è¬æ¿èªãã¿ïŒ
ããã¥ã¡ã³ã¿ãªãŒã®ç¶ãããªã¢ã«ã¿ã€ã ã§äœéšã
ããã¥ã¡ã³ã¿ãªãŒã®ç¶ãããªã¢ã«ã¿ã€ã ã§äœéšã
æ ªäŸ¡äžæã«ããææã§ã㪠/ âã¢ã«ããã€ããŒç
ã®æ°è¬ ç±³FDAæ¿èªãšçºè¡š ãšãŒã¶ã€ãå
±åéçº | å»ç â
âã¢ã«ããã€ããŒç
ã®æ°è¬ ç±³FDAæ¿èªãšçºè¡š ãšãŒã¶ã€ãå
±åéçº | å»ç â
仿¥å人çã«èå³ãæ¹ãããã®ã¯ããã®ãã¥ãŒã¹ã
ããŒãã«è³ãåè³ãããããªäººãã¢ã«ããã€ããŒã«ãªã£ãŠããã§ãçºçã®æ©åºãæªã ã«è¯ãåãããªãã
ã¢ã«ããã€ããŒç ã®æ°è¬ ç±³FDAæ¿èªãšçºè¡š ãšãŒã¶ã€ãå ±åéçº
ããŒãã«è³ãåè³ãããããªäººãã¢ã«ããã€ããŒã«ãªã£ãŠããã§ãçºçã®æ©åºãæªã ã«è¯ãåãããªãã
ã¢ã«ããã€ããŒç ã®æ°è¬ ç±³FDAæ¿èªãšçºè¡š ãšãŒã¶ã€ãå ±åéçº
èªç¥çãäºé²ãã
æ²»çã®æä»£ãž
æ²»çã®æä»£ãž
ã¿ããªãããåãããã¢ã«ãã®åå ã®ã¢ããã€ãβãåãé€ãäœçšãããããããæ¥æ¬ã§ãæ¿èªç³è«ãåºãŠããããããå°ãã§åºããããå£ããè³çްèã¯å
ã«æ»ããããã軜床èªç¥ç察象ããã©ãã
ã¢ã«ããã€ããŒç ã®æ°è¬ ç±³FDAæ¿èªãšçºè¡š ãšãŒã¶ã€ãå ±åéçº
ã¢ã«ããã€ããŒç ã®æ°è¬ ç±³FDAæ¿èªãšçºè¡š ãšãŒã¶ã€ãå ±åéçº
ã¢ããã€ãããŒã¿ãæšçãšããã¢ã«ããã€ããŒç
ã®æ²»çè¬ãFDAã«æ¿èªãããŸããïŒ
æ¥æ¬ã§ãæ¿èªãããã®ãåŠãããæ¥æ¬äººãšããŠã¯æ°ã«ãªããŸããã
æ¥æ¬ã§ãæ¿èªãããã®ãåŠãããæ¥æ¬äººãšããŠã¯æ°ã«ãªããŸããã
ðã¢ã«ããã€ããŒç
ã®æ°è¬ ç±³FDAæ¿èªãšçºè¡š ãšãŒã¶ã€ãå
±åéçº
ãåºæïŒ / å³éžã
ãåºæïŒ / å³éžã
>ãã¢ãã¥ã«ããããã¯çç¶ã®é²è¡ãæããããšãç®çãšããè¬ã§ãè³ã«ããŸã£ããã¢ããã€ãβããšåŒã°ããç°åžžãªããã±ã質ãåãé€ããç¥çµçްèãå£ããã®ãé²ããã¢ã«ããã€ããŒç
ã®æ°è¬ãæ¿èªãããã®ã¯2003幎以æ¥18幎ã¶ãã§ãã¢ããã€ãβã«äœçšããæ²»çè¬ã¯åããŠ
ã¢ã«ããã€ããŒç
ã®æ°è¬ ç±³FDAæ¿èªãšçºè¡š ãšãŒã¶ã€ãå
±åéçº
äžããæ¹ãå端ãªãã補è¬äŒç€Ÿã¯ã®ã£ã³ãã«æ§ãé«ããã
äžããæ¹ãå端ãªãã補è¬äŒç€Ÿã¯ã®ã£ã³ãã«æ§ãé«ããã
ïŒ
ðã¢ã«ããã€ããŒç ã®æ°è¬ ç±³FDAæ¿èªãšçºè¡š ãšãŒã¶ã€ãå ±åéçº ïŒŒ
ðã¢ã«ããã€ããŒç ã®æ°è¬ ç±³FDAæ¿èªãšçºè¡š ãšãŒã¶ã€ãå ±åéçº ïŒŒ
ãããŒã察åŠçæ³è¬ãããªããŠé²è¡ãæå¶ããã®ã£ãŠäžçåã ã£ãã®ãã
ã¢ã«ããã€ããŒç ã®æ°è¬ ç±³FDAæ¿èªãšçºè¡š ãšãŒã¶ã€ãå ±åéçº
ã¢ã«ããã€ããŒç ã®æ°è¬ ç±³FDAæ¿èªãšçºè¡š ãšãŒã¶ã€ãå ±åéçº
ææã¡ã®ç¬¬äžäžå
±ã®å«ã¿çã倧å¹
æžå°ããŠãããªãã§ããšãŒã¶ã€ã®ãã®ãã¥ãŒã¹ã«å°ãã»ã£ãšããŸããã
ãŸãâŠç¬¬äžäžå ±3600æ ªãšãšãŒã¶ã€500æ ªä¿æã ãããã¡ãŒãžã®æ¹ããŸã 倧ããã®ã ããã©(ç¬)
ãŸãâŠç¬¬äžäžå ±3600æ ªãšãšãŒã¶ã€500æ ªä¿æã ãããã¡ãŒãžã®æ¹ããŸã 倧ããã®ã ããã©(ç¬)
ïŒé¢é£èšäºïŒ
âŠFDAã¯7æ¥ãèšåºè©Šéšã®çµæããã¢ããã€ãβãã®æžå°ã確èªãããæ£è ã®çç¶ãžã®å¹æãåççã«äºæž¬ãããããšè©äŸ¡ãæ²»çè¬ãšããŠæ¿èªãããšçºè¡šããŸããã
âŠFDAã¯7æ¥ãèšåºè©Šéšã®çµæããã¢ããã€ãβãã®æžå°ã確èªãããæ£è ã®çç¶ãžã®å¹æãåççã«äºæž¬ãããããšè©äŸ¡ãæ²»çè¬ãšããŠæ¿èªãããšçºè¡šããŸããã
â ã¢ã¡ãªã«è£œè¬äŒç€Ÿããã€ãªãžã§ã³ãæ¥æ¬ããšãŒã¶ã€ããå
±åã§éçº â æ°è¬ãã¢ãã¥ã«ãããã
ðã¢ã«ããã€ããŒç ã® å¹ææåŸ ãããåããŠã®è¬ïŒïŒ
ðã¢ã«ããã€ããŒç ã® å¹ææåŸ ãããåããŠã®è¬ïŒïŒ
ã¢ã«ããã€ããŒç
ã®æ°è¬ ç±³FDAæ¿èªãšçºè¡š ãšãŒã¶ã€ãå
±åéçº
ã¢ãã¥ã«ããããåãæ¶ãã®å¯èœæ§ããããŸããFDAã§æ¿èªãããŸãããâŠãèšåºè©Šéšã®çµæã¯åŸåºãã§å€§ããã¯ãªãäžã«ãå¯äœçšã®ARIAã倿°åºãŠãŸãããæ¥æ¬ã¯èœã¡çããŠååãã¿ãŠæ¬²ããã§ãã
ã¢ãã¥ã«ããããåãæ¶ãã®å¯èœæ§ããããŸããFDAã§æ¿èªãããŸãããâŠãèšåºè©Šéšã®çµæã¯åŸåºãã§å€§ããã¯ãªãäžã«ãå¯äœçšã®ARIAã倿°åºãŠãŸãããæ¥æ¬ã¯èœã¡çããŠååãã¿ãŠæ¬²ããã§ãã
ã©ãã»ã©å€ãã®æ£è
ãšå®¶æããã®ç
æ°ã§èŠããã§ããäºããäžçãå€ããããç¥ããªãæ¬åœã«çŽ æŽããããã¥ãŒã¹ã âŒïž
NHKã¿ããã«ããšãŒã¶ã€ãããïŒããšããæžããªãæ¥æ¬ã¡ãã£ã¢ãšãéå ±ã¬ãã«ã§å®éã®å¹æã¯çããããšã®ææã䜵ããŠåºãã¢ã¡ãªã«ã®ã¡ãã£ã¢ãèŠãŠãå
¬å¹³ãªå ±éã£ãŠäœã ãããšæã
New Alzheimerâs drug is 1st of its kind to be FDA approved
New Alzheimerâs drug is 1st of its kind to be FDA approved
1stâ圡âºð
äžåºŠã¯ãã³ãã£ã³ã°ãããŠã©ããªãããšæã£ãŠãããã©ãæ¿èªãããŠè¯ãã£ããéçºæéãé·ãã®ã§é«é¡ã«ãªãäºæã¯ãããã©ã
âã¢ã«ããã€ããŒç
ã®æ£è
ã®è³ã«ããç°åžžãªããã±ã質ããã¢ããã€ãβããåãé€ãããšã§è³ã®ç¥çµçްèãå£ããèªç¥æ©èœãäœäžããã®ãé²ãããšãããã®â
ãšãŒã¶ã€ã®æ²é¡
ã¢ã«ããã€ããŒã®æ ¹æ¬æ²»çè¬ãã§ãããšãæªæ¥äºæž¬ã®äžçã®ã¿ããšæã£ãŠããã©ãåãæä»£ã«ãªã£ã
å®¶æã«éå»ã«çœ¹æ£è ãããè ãšããã°è€éãªæ°æã¡ã«ãªããã©
ä»è·è·ã®æ¹ã ã¯å©çšè ãšã®ææçéãåããããã«ãªãã ãã§è² æ ã¯å€§å¹ ã«æžãã¯ã
å®¶æã«éå»ã«çœ¹æ£è ãããè ãšããã°è€éãªæ°æã¡ã«ãªããã©
ä»è·è·ã®æ¹ã ã¯å©çšè ãšã®ææçéãåããããã«ãªãã ãã§è² æ ã¯å€§å¹ ã«æžãã¯ã
ãã®æãåŸ
ã£ãŠãã
ããŒãã³ãœã³ç
ã®æ²»çè¬ãåºæ¥ããšãããªããã¡ããã³ãããŠã€ã«ã¹ãâŠ
ãšãŒã¶ã€ããã°ã£ãŠïŒ
ã»ãã
æåŸ
ã§ããªãçãªãã¥ãŒã¹èŠãŠãããã©æ¿èªããããã ãããã§ãšãð
ã¢ã«ããã€ããŒç
ã®è¬
ã¢ã«ããã€ããŒç
ã¢ã¡ãªã«ã®FDAïŒé£åå»è¬åå±ã¯ãæ¥æ¬ã®ãšãŒã¶ã€ãšã¢ã¡ãªã«ã®è£œè¬äŒç€Ÿãã€ãªãžã§ã³ãå
±åéçºããã¢ã«ããã€ããŒç
ã®è¬ã7æ¥ãæ¿èªãããšçºè¡šããŸããããã®è¬ã¯ãã¢ã«ããã€ããŒç
ã®æ£è
ã®è³ã«ããç°åžžãªããã±âŠ
ææ°ã³ã¡ã³ã10ä»¶ïŒ06/08 01:55ïŒ
ããã¯æå ±ãããå¥åº·ã«çããããè¬ã¯å€ãã»ãããã
ã¢ããã€ãβãåãé€ãã ãšâŠïŒ
æAβæäœã§ããã¢ãã¥ã«ããããç±³FDAã§æ¿èªãããŸããã远å ã®èšåºè©Šéšã§æ€èšŒãå¿ èŠãšããæ¡ä»¶ä»ãã§ããã2003幎以æ¥ã®æ°èŠæ¿èªã§ããæ¥æ¬ã§ãç³è«äžã§ãã®ã§ä»åŸã®ååã«æ³šç®ãããŸãã